

Evaluation of Serum Lipid Profile and Malondialdehyde Levels in Obese Adults

Ugochukwu C.P.,¹ Meludu S.C.,² Ugwu C.E.,³ Ofor I.B.,⁴ Onitsha E.N.,⁵ Nezianya E U.⁶

¹*Department of Medical Laboratory Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria

² Department of Biochemistry, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria

³ Department of Biochemistry, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria

⁴Department of Medical Laboratory Services, Federal Medical Centre Yenagoa Bayelsa State, Nigeria

⁵ Department of Medical Laboratory Sciences, Niger Delta University, Amassoma, Bayelsa State, Nigeria

⁶ Department of Public Health, University of Lagos.

DOI: 10.29322/IJSRP.11.07.2021.p11596
<http://dx.doi.org/10.29322/IJSRP.11.07.2021.p11596>

Abstract- Their anthropometrics (weight, height, and blood pressure) were also taken using standardized media. The result showed a statistically significant ($P < 0.05$) increase in the mean value of total Cholesterol, triglyceride and LDL-C, and a statistically significant ($P < 0.05$) decrease in HDL-C in the obese group when compared with control (normal weight) group. There was also statistically significant ($P < 0.001$) increase in atherogenic indices (TC/HDL-C, LDL-C/HDL-C) in the both the overweight and normal weight groups compared with the obese group. There was negative statistically significant ($P < 0.05$) correlation between TC, LDL-C and atherogenic indices in relation to TAC. In the obese group, there were statistically significant positive correlations between TC, TC/HDL-C, LDL-C/HDL-C, LDL-C with MDA. There is significant ($P < 0.05$) increase in the serum levels of MDA in relation to BMI while TAC showed a significant ($P < 0.05$) decrease in relation to the BMI. The decrease in antioxidant defenses and increases in TC, TG and LDL-C in obese subjects reflects [oxidative stress](#). This could be one of the mechanisms involved in the onset of diseases caused by obesity.

Index Terms- Body Mass Index, Lipid profile and Oxidative Stress

I. INTRODUCTION

Obesity is a [medical condition](#) in which excess [body fat](#) has accumulated to the extent that it may have a negative effect on health, leading to reduced [life expectancy](#) and increased health problems ⁽¹⁾. It is assuming an epidemic dimension globally ⁽²⁾. Aside from being a potentially modifiable cardiovascular diseases (CVDs) risk factor on its own, this non-communicable disease predisposes to other CVD risk factors such as diabetes mellitus, hypertension and dyslipidemia among others ⁽³⁾. Usually assessed by [Body Mass Index](#) (BMI), excess weight (Obesity and overweight) is a risk factor of atherosclerosis, and it is normally attributed in some extent to non-insulin dependent diabetes mellitus, arterial hypertension and hyperlipidemia. This atherogenic effect of obesity could be associated to several mechanisms which include inflammatory mechanisms, insulin resistance and stimulation of renin-angiotensin system commonly related to atherosclerosis processes ^(4,5).

Lipid profile, a panel of investigations considered as obesity related-indicators is used to identify [dyslipidemia](#), many forms of which are recognized risk factors for CVD. It measures total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol and triglycerides. Lipids are insoluble in water but are soluble in alcohol and other solvents. When dietary fats are digested and absorbed into the small intestine, they eventually re-form into triglycerides, which are then packaged into lipoproteins. Dietary fats, including cholesterol, are absorbed from the small intestines and transported into the liver by lipoproteins called chylomicrons. After a 12-14 hour fast, chylomicrons are absent from the bloodstream ⁽⁶⁾. The liver removes the chylomicron fragments, and the cholesterol is repackaged for transport in the blood in very low-density lipoproteins (VLDLs), which eventually turn into low-density lipoproteins (LDL). LDL cholesterol (LDL-C)—the "bad cholesterol"—consists mainly of cholesterol ⁽⁷⁾.

Dyslipidemia, commonly manifested as high plasma triglyceride levels, low HDL-C with normal LDL-C and high triglyceride level are important features observed in obesity and there is also a correlation between the degree of obesity and plasma level of LDL cholesterol and triglycerides ⁽⁸⁾. Total antioxidant activity of serum is part of a tightly regulated homeostatic mechanism ⁽⁸⁾. When antioxidant defenses are weakened, as seen in obese people with greater energy expenditure than their thin counterparts due to the energy required to maintain an increased body mass ⁽⁹⁾, risk of developing CVD may likely increase. Evaluation of total antioxidants capacity in body fluid has been used as one of the biological markers for monitoring oxidative stress in humans ⁽¹⁰⁾.

Malondialdehyde(MDA) is one of the most frequently used indicators of lipid peroxidation. Previous studies have shown that the mean MDA levels are higher in obese individuals compared to nonobese healthy controls ⁽¹¹⁾. It is also shown that obesity is associated with increases in endogenous lipid peroxides and oxidation of low-density lipoproteins ⁽¹²⁾. Whether the increased lipoprotein oxidizability is due to enhanced oxidant challenge, or decreased antioxidant content, or changed lipoprotein composition is not fully explained.

Obesity with dyslipidemia has been shown to promote the onset of CVD. This link is strongly related to oxidative stress. Low levels of circulating high-density lipoprotein (HDL), enhanced

clearance of HDL particles, increased post-prandial TG values, and elevated plasma very low density-lipoprotein (VLDL) levels promote ROS generation in the endothelium. In addition to a pro-inflammatory process, ROS can also directly damage lipids, proteins or DNA and modulate intracellular signaling pathways, such as mitogen activated protein kinases and redox sensitive transcription factors, causing changes in protein/lipid expression and, therefore, irreversible oxidative damage⁽¹³⁾.

II. METHODS

Study Area

The study was carried out in Nnewi, Anambra state Nigeria. Nnewi is located 6.02 latitude and 6.92 longitude and it is situated at elevation 151 meters above sea level. Nnewi is one of the largest cities in Anambra State, South Eastern Nigeria. It has two local government areas, Nnewi North and Nnewi South; Nnewi North is commonly referred to as Nnewi central. According to the Nigerian census the city spans over 1,076.9 square miles with an estimated population of 391,227. It is about 216 miles (or 347 km) South of Abuja, the nation's capital and the principal inhabitants of the city are Igbos and their occupation is majorly trading and farming, although some few are involved in production.

Subjects

This study recruited a total of one hundred and ninety-eight apparently healthy volunteers, one hundred and thirty-four were overweight and obese while the other sixty-four were normal weight. They were within the ages of 18-60 and resident within Nnewi metropolis. Those that were disabled, having a weight of <18.5 kg or having any metabolic condition were excluded from the study. All participants in this study gave Informed consent and ethical approval was obtained from the ethical committee of Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra state.

Sample Collection

Blood samples (6.0 mL) were obtain from each subject between the hours of 08.00-10.00 after overnight fast and dispensed into plain bottles and allowed to clot for about two (2) hours. The samples were centrifuged at 3000 rpm for five (5) min, after which serum was isolated from the clot and aliquoted into dry plain plastic screw-capped containers and stored frozen at -20°C prior to analyses

Analysis of Biochemical Parameters

The analysis for Total cholesterol was carried out colorimetrically using Enzymatic Endpoint Method⁽¹⁴⁾. The cholesterol is determined after enzymatic hydrolysis and oxidation. The indicator quinoneimine is formed from hydrogen peroxide and 4-aminoantipyrine in the presence of phenol and peroxidase. While triglycerides are determined after enzymatic hydrolysis with lipases. The indicator is a stable red quinoneiminedye formed from hydrogen-peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic influence of peroxidase. Low density lipoproteins were precipitated quantitatively by the addition of phosphotungstic acid in the presence of magnesium ions. After centrifugation, the cholesterol concentration in the HDL (high density lipoprotein) fraction,

which remains in the supernatant was determined. The LDL-Cholesterol concentration was extrapolated from Friedwald's formula⁽¹⁵⁾

$LDL\text{-Cholesterol} = \text{Total cholesterol} - \text{Triglyceride} - \text{HDL-Cholesterol} / 2.2$. Malondialdehyde(MDA) is a product of lipid peroxidation. When heated with 2-thiobarbuturic acid (TBA) under alkaline condition, it forms a pink coloured product, which has absorption. Sample was assayed for TAC on spectrophotometer with a commercially available TAS kit ("Total Antioxidant Status" – TAS; Randox, Crumlin, UK), following the instructions of the manufacturers. Antioxidants in the sample reduce dark blue-green colored ABTS radical to colorless reduced ABTS form. The change of absorbance at 660nm is related with total antioxidant level of the sample. The assay is calibrated with a stable antioxidant standard solution which is traditionally named as Trolox Equivalent that is a vitamin E analog⁽¹⁶⁾.

Data Analysis

Data was reported as mean \pm SD. Statistical comparisons was made using the Student t-test in SPSS version 19. Pearson's correlation coefficients was also used to assess the relationship between total antioxidant capacity, malondialdehyde levels and lipid profile. The correlation between these parameters and the different BMIs was assessed by Spearman's correlation coefficient. In all analysis, p

Results

Table 4.1 shows Antropometric variables in normal, overweight and obese individuals (Mean \pm SD). There was increase in age of the participants. This increase was statistically significant between groups A and B (P=0.039) as well as A and C (P<0.001), but the increase between groups B and C was not statistically significant (P> 0.05). There was however a significant increase (P<0.05) in the weight of the participants as well as in their BMI. The comparison of the weight and BMI in all the three groups also showed significant increase (P<0.05). However, the mean heights of the participants in the three groups followed an irregular pattern and when compared against each other there was no statistical significance. There was significant increase (P<0.05) in both systolic and diastolic blood pressure, between groups A and C as well as groups B and C. The results also showed that DBP increased significantly (P<0.05) in group A relative to group B while there was no significant increase (P>0.05) in SBP between groups A and B. **Table 4.2** shows Serum lipid profile in the normal, overweight and obese individuals ((Mean \pm SD). TC, TG and LDL-C showed significant (P<0.05) increase in relation to BMI, while HDL-C decreased relative to BMI, this was only significant (P<0.05) between groups B and C. The results show that there was no significant (P>0.05) increase in the mean TG, HDL-C and LDL-C between groups A and B but TC was significantly (P<0.05) increased in these groups. However, there was a significant (P<0.05) increase in the mean of TC, TG and LDL-C when compared between groups A and C as well as groups B and C. The results also indicated a significant (P<0.05) decrease in mean HDL-C between groups A and C. **Table 4.3** shows Serum levels of total antioxidant capacity(TAC), malondialdehyde (MDA) in normal, overweight and obese individuals. There was significant (P< 0.05) increase in the serum levels of MDA in relation to BMI while TAC showed a significant (P<0.05)

decrease in relation to the BMI. There was no significant ($P>0.05$) decrease between normal weight and overweight individuals with respect to total antioxidant capacity (TAC) neither was there significant increase in mean serum levels of malondialdehyde between the normal weight and overweight group. However, group A (normal weight) and C (obese) as well as B (overweight) and C showed significant ($P<0.05$) decrease in TAC, while groups A and C showed significant ($P<0.05$) increase in MDA. There was however no significant ($P>0.05$) increase in MDA between groups B and C. There was significant ($P<0.05$) increase in Apo B in relation to BMI, between groups A and C as well as groups A and B there were significant increase. However, between groups B and C the increase was not statistically significant ($P>0.05$). **Table 4.4** shows serum levels of atherogenic Indexes in normal, overweight and obese individuals. There was significant

($P<0.001$) increase in all three atherogenic indices and this also reflected in the comparison of group A (normal weight) and C (obese) as well as in groups B (overweight) and C (obese). However, groups A (normal) and B (overweight) showed no significant ($p>0.05$) increase in the atherogenic indices measured. There was significant ($P<0.05$) increase in relation to BMI and this increase was significant ($P<0.05$) in comparison between various groups.

Table 4.1: Anthropometric variables in Normal, Overweight and Obese Individuals

GROUP	AGE (years)	WEIGHT(Kg)	HEIGHT(m)	BMI(Kg/m ²)
A	34.20±10.50	63.06±8.96	1.67±0.07	22.02±1.81
B	38.00±10.88	78.80±8.32	1.68±0.09	27.81±1.19
C	40.61±9.70	94.00±13.39	1.67±0.08	33.54±3.36
f-value	6.453	142.727	0.789	375.781
p-value	0.002*	<0.001*	0.456	<0.001*
A Vs B	p=0.039*	p<0.001*	p=0.448	p<0.001*
A Vs C	p<0.001*	p<0.001*	p=0.587	p<0.001*
B Vs C	p=0.146	p<0.001*	p=0.211	p<0.001*

Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant ($P<0.05$). Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant ($P<0.05$). Group A: Normal Weight, Group B: Overweight, Group C: Obese.

Table 4.2: Serum lipid profile parameters in normal, overweight and obese individuals.

GROUP	TC (mmol/l)	TG (mmol/l)	HDL-C (mmol/l)	LDL-C (mmol/l)
A	4.58±0.82	0.85±0.32	1.19±0.37	3.01±0.74
B	4.89±1.06	1.03±0.56	1.23±0.37	3.23±0.97
C	5.40±0.78	1.33±0.60	1.11±0.31	3.60±0.82
f-value	14.739	15.015	2.209	8.265
p-value	<0.001*	<0.001*	0.113	p<0.001*
A Vs B	p=0.049*	p=0.051	p=0.463	p=0.151
A Vs C	p<0.001*	p<0.001*	p=0.189	p<0.001*
B Vs C	p=0.001*	p=0.001*	p=0.040*	p=0.012*

Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant ($P<0.05$). Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant ($P<0.05$). Group A: Normal Weight, Group B: Overweight, Group C: Obese, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol.

Table 4.3: Serum levels of total antioxidant capacity (TAC), malondialdehyde (MDA) in normal, overweight and obese individuals.

GROUP	TAC (Umol/l)	MDA (nmol/l)
A	1036.10±195.43	1.58±0.83
B	1061.90±170.56	1.92±1.55

C	957.76±115.57	2.18±1.48
f-value	7.521	3.390
p-value	0.001*	0.036*
A Vs B	p=0.371	p=0.152
A Vs C	p=0.006*	p=0.010*
B Vs C	p<0.001*	p=0.259

Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant (P<0.05). Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant (P<0.05). Group A: Normal Weight, Group B: Overweight, Group C: Obese, TAC=total antioxidant capacity, MDA= Malondialdehyde

Table 4.4 Serum levels of atherogenic Indices in normal, overweight and obese individuals.

GROUP	TC/HDL-C	LDL-C/HDL-C	TG/HDL-C
A	4.15±1.32	2.30±1.20	0.78±0.37
B	4.26±1.46	2.88±1.31	0.91±0.56
C	5.29±1.71	3.59±1.44	1.33±0.77
f-value	11.716	7.393	15.703
p-value	<0.001*	0.001*	<0.001*
A Vs B	p=0.670	p=0.742	p=0.214
A Vs C	p<0.001*	p=0.001*	p<0.001*
B Vs C	p<0.001*	p=0.002*	p<0.001*

Results of Mean ±Sd of Duplicate Readings; *=Statistically Significant (P<0.05). Group A: Normal Weight, Group B: Overweight, Group C: Obese, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol.

III. DISCUSSION

The most important risk factors for cardiovascular disease consist of dyslipidemia, hypertension, obesity, physical inactivity, poor diet and smoking. Among these, lipid profile of plasma is the major risk factors and predictor for cardiovascular disease (17,18). Dyslipidemia describe as elevated plasma concentration of lipid (triglyceride (TG) and total cholesterol (TC) and their blood transporting lipoproteins; HDL- Cholesterol, LDL-Cholesterol, VLDL-Cholesterol) (19).

This study demonstrated that there is a concordance between increased BMI and significant increase in value of LDL-C, TC and TG as well as systolic blood pressure and diastolic blood pressure and a significant decrease in HDL-C. This result is similar to the results of Kearn *et al.* (20) and several cross-sectional studies that showed chronic diseases like hypertension, diabetes, dyslipidemia and osteoarthritis are more prevalent in obese persons(21,5). Strong scientific evidence indicates that there is a strong association between incidence of cardiovascular disease and high level of LDL-C and also low level of HDL-C (16). On the other hand, high level of TG has been related with an increased LDL-C particle and increased cardiovascular risk (17). On that basis, atherogenic dyslipidemia, defined as high LDL-C/HDL-C ratio and hyper TG, is associated with high cardiovascular risk (18). Obesity is associated with an increased risk of developing atherosclerosis.

Oxidative modification of lipoproteins may play an important role in the pathogenesis of atherosclerosis. Lipid peroxidation is involved in the oxidative modifications of low-density lipoproteins and this ultimately results in the formation of atherosclerotic lesions. Malondialdehyde is one of the most frequently used indicators of lipid peroxidation. Previous studies have shown that the mean MDA levels are higher in obese individuals compared to non-obese healthy controls (11). It is also shown that obesity is associated with increases in endogenous lipid peroxides and oxidation of low-density lipoproteins (12). In another study it was demonstrated that lipoprotein oxidizability is enhanced in obese young women, uncomplicated by hypertension, hypercholesterolaemia, diabetes or coronary heart disease (22). In our study we also found high MDA levels in obese subjects than in non obese. Whether the increased lipoprotein is due to enhanced oxidant challenge, or decreased antioxidant content, or changed lipoprotein composition is not fully explained. Our result in line with previous studies indicated that obesity is associated with increases in endogenous lipid peroxides. The indicator of lipid peroxidation—MDA—decreased with weight loss (23).

Dyslipidemia is defined as a condition of high blood cholesterol and TG levels that can increase the risk of cardiovascular disease, stroke, and other health problems. Obesity with dyslipidemia has been shown to promote the onset of cardiovascular disease. This link is strongly related to oxidative stress. In this study, malondialdehyde was strongly positively

- [16] Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. *J Clin Pathol*. 2001 May;54(5):356-61.
- [17] treatment with niacin and chromium on the liver of hyperlipemic rats. *Biological Trace Elements Res*; 101:219–229.
- [18] Yang, R., Shi, Y., Hao, G., Li, W. and Le, G. (2008) Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index. *Journal of Clinical Biochemistry and Nutrition*; 43:154–158.
- [19] Kershaw, E. and Flier, J. (2004). Adipose tissue as an endocrine organ; *Journal of Clinical Endocrin Metab*; 89:2548-2556.
- [20] Kearns, K., Dee, A., Fitzgerald, A., Doherty, E. and Perry, I. (2014). Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level. *BMC Public Health*; 14:143
- [21] Van Gaal, L., Vertommen, J. and De Leeuw, I. (1998) The in vitro oxidizability of lipoprotein particles in obese and non-obese subjects. *Atherosclerosis*; 137: 39–44.
- [22] Shabnam, N., Mohammad, K., Majid, K., Maryam A., Mohammadreza, J., Gholamhasan K. and Maliheh, D. (2015). Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. *Medical Journal of Islamic Republic of Iran*; 29:240.
- [23] Savini, I., Catani, M., Evangelista, D., Gasperi, V. and Avigliano, L. (2013) Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State. *International Journal Molecular Science*; 14: 10497-10538
- [24] Fernández-Sánchez, A., Madrigal-Santillán, E., Bautista, M., Esquivel-Soto, J. and Morales onzález, Á. (2011). Inflammation, Oxidative Stress, and Obesity. *International Journal of Molecular Science*; 12: 3117-3132
- [25] Nwagha U., Ikekpeazu E., Ejezie F., Neboh E. and Maduka I. (2010) Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. *African Health Sciences*; 10(3):248–252.
- [26] Rao, V., and Kiran, R. (2011). Evaluation of correlation between oxidative stress and abnormal lipid profile in coronary artery disease. *Journal of cardiovascular disease research*, 2(1), 57
- [27] Petelin A, Tedeschi P, Maietti A, Jurdana M, Brandolini V, Pražnikar ZJ. (2017) Total Serum Antioxidant Capacity in Healthy Normal Weight and Asymptomatic Overweight Adults. *Exp Clin Endocrinol Diabetes*. 2017 Jul;125(7):470-477.
- [28] Wha Ha, A., Su Youn Jeong, S. Kang, N. and Kyoung Kim, W. (2014). Plasma adipocytokines and antioxidants-status in Korean overweight and obese females with dyslipidemia. *Nutrition Research and Practice*; 8(4):417-424
- [29] Essiarab, F., Taki, H., Lebrazi, H., Maati Sabri, M. and Sai'le, R. (2014). Usefulness of lipid ratios and atherogenic index of plasma in obese Moroccan women with or without metabolic syndrome. *Ethnicity & Disease*; 24:207-2.
- [30] Femlak, M., Gluba-Brzózka, A., Ciałkowska-Rysz, A. et al (2017). The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. *Lipids Health Dis* 16 ,207

AUTHORS

First Author – Ugochukwu C.P, Department of Medical Laboratory Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria
Second Author – Meludu S.C, Department of Biochemistry, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria
Third Author – Ugwu C.E, Department of Biochemistry, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Anambra State, Nigeria
Fourth Author – Ofor I.B, Department of Medical Laboratory Services, Federal Medical Centre Yenagoa Bayelsa State, Nigeria
Fifth Author – Onitsha E.N, Department of Medical Laboratory Sciences, Niger Delta University, Amassoma, Bayelsa State, Nigeria
Sixth Author – Neziyanya E U, Department of Public Health, University of Lagos.

Corresponding Author: Onitsha Enebrayi Nelson E-mail: Bray4life@gmail.com; Tel: +2347030603518